CV – C. Klein

Scientific CV

Christian Klein Professor of Pharmaceutical Chemistry at Heidelberg University Dr. rer. nat. c.klein@uni-heidelberg.de Institut für Pharmazie und Molekulare Biotechnologie Im Neuenheimer Feld 364 D-69120 Heidelberg Tel. 06221 54-4875

University Education

1990-1994 Undergraduate studies in Pharmacy at Bonn University and Swiss Federal Institute of Technology Zurich (ETH)

Practical Training and Military Service

Nov. 1994 – April 1995 Pharmaceutical practical training in a pharmacy Mai – Oktober 1995 Pharmaceutical practical training at Bayer AG, Leverkusen

Jan. – Oktober 1996 (Compulsory) Military Service as Pharmacist Ph.D.

Nov. 1996 - Jan. 2000 Research at Universität Bonn and University of Illinois, Chicago, as a Fellow of the Konrad-Adenauer-Foundation

Jan. 2000 Ph.D. examination "summa cum laude" Scientific career after the Ph.D. March 2000 – March 2001 Post-Doc at Universität des Saarlandes, Saarbrücken,

established an independent research project. April 2001 – March 2003 Post-Doc at ETH Zürich, Switzerland April 2003 – March 2004 Post-Doc at Univ. des Saarlandes, Saarbrücken

April 2004 Independent group leader in the Emmy-Noether-program of Deutsche Forschungsgemeinschaft

2007 Received two offers of professorships, W3 (Heidelberg University, Leipzig University)

Since August 2007 Professor of Pharmaceutical Chemistry at Heidelberg University

Since Jan. 2012 Managing director of the Institute of Pharmacy and Molecular Biotechnology, Heidelberg University

Honors etc.

2000 Award for the Ph.D. thesis, by the German Pharmaceutical Society

2009 "Chairman of the Board" of "Frontiers in Medicinal Chemistry 2009" (Joint Congress of German Chemical Society, German Pharmaceutical Society, and Swiss Chemical Society)

Since 2011 Regional group head of German Pharmaceutical Society Since 2011 Liaison professor of the Konrad-Adenauer-Stiftung Since 2012 Member of the steering committee, Chemical Biology Core

Facility of DKFZ/EMBL/Univ. Heidelberg

CV – C. Klein

Present and past funding by: DFG KL-1356; DFG KFO-129; DFG INST 35/836-1 FUGG; Deutsche Krebshilfe; MWFK Baden-Württemberg – Förderprogramm Biotechnologie; BMWi Pro-Inno-2 Selected Publications:

Nitsche, C., Behnam, M.A. Steuer, C., Klein, C.D.* Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Research, 2012, 94, 72-79. Steuer, C., Gege, C., Fischl, W., Heinonen, K.H., Bartenschlager, R., Klein, C.D.* Synthesis and biological evaluation of α -ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. Bioorganic & Medicinal Chemistry 2011, 19, 4067-4074 Mendgen, T., Steuer, C., Klein, C.D.* Privileged Scaffolds or Promiscuous Binders – A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry. Journal of Medicinal Chemistry, 2011, 55, 743–753. Nitsche, C., Steuer, C., Klein, C.D.* Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. Bioorganic & Medicinal Chemistry, 2011, 19, 7318-7337 Steuer, C., Heinonen, K., Kattner, L., Klein, C.D.* Optimization of Assay Conditions for Dengue Virus Protease: Effect of Various Polyols and Non-Ionic Detergents. J. Biomol. Screening, 2009, 14, 1102-1108 Ziegler, S., Kronenberger, B., Albrecht, B., Kaul, A., Gamer, A., Klein, C.D.* , Hartmann, R.W.* Development and Evaluation of a FACS-Based Medium Throughput Assay for HCV Entry Inhibitors. J. Biomol. Screening, 2009, 14, 620-626 Steinbach, A., Scheidig, A.J., Klein, C.D.* The unusual binding mode of cnicin to the antibacterial target enzyme MurA revealed by X-ray crystallography. J. Med. Chem., 2008, 51, 5143-5148 Neugebauer, A.; Hartmann, R.W.; Klein C.D.* Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J. Med. Chem., 2007, 50, 4665-4668 Schiffmann, R.; Heine, A.; Klebe, G.; Klein, C.D.* Metal Ions as Cofactors for Ligand Binding at Methionine Aminopeptidase: A Critical View on the Relevance of in vitro Metalloenzyme Assays. Angewandte Chemie Int. Ed. 2005, 44, 3620-3623 Patent Applications: Bading, H.; Klein, C.; Mauceri, D. VEGF-D/VEGFR2/3-mediated regulation of dendrites. PCT/EP2012/002333 Joest, C.; Klein, C.; Miller, A. New spiroepoxide tetrahydrobenzo-triazoles and -imidazoles and their use as MetAP-II inhibitors. EP 12006666, 22. Sept. 2012

Interests: Design and discovery of small molecules with biological activity. A particular focus is laid on novel and unusual mechanisms of action, on antiinfective compounds, and on compounds with a potential application in regenerative medicine and synthetic biology. Core competencies and methods: � Rational design of novel ligands and inhibitors, based on the structures of target proteins,

natural ligands or substrates, and other available knowledge. � Development of screening and assay systems, particularly for enzymatic activities. � Medium-throughput screening with optical (UV-VIS, fluorescence, etc.), chromatographic

(HPLC-UV, HPLC-fluorescence) and mass-spectrometric readout. � Heterologous expression, purification and characterization of target proteins � Synthetic organic chemistry, ranging from small to medium-sized (peptidic) molecules.

This includes parallel organic synthesis, peptide synthesis, all methods of compound characterization (state-of-the-art equipment for NMR, HPLC-MS, circular dichroism, combustion analysis, etc.).